Physician profile

David Knox Booth

Family Medicine · Greenwood, IN

NPI 1144250689

$4,111.57

in general payments reported to CMS, 2019-2025

38 companies · $646 in 2025

The $646 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,228.87
Education$0.79

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $691.41 2019-2025 Ozempic, Wegovy, Saxenda
Abbvie INC. $612.03 2019-2025 Vraylar, Qulipta, Ubrelvy
Glaxosmithkline, LLC. $328.56 2019-2025 Shingrix, Trelegy Ellipta, Arexvy
Astrazeneca Pharmaceuticals LP $282.38 2019-2025 Airsupra, Farxiga, Breztri
Pfizer INC. $272.72 2019-2025
Lilly USA, LLC $151.85 2023-2024 Mounjaro, Zepbound, Basaglar
Merck Sharp & Dohme LLC $148.76 2019-2025 Gardasil 9, Vaxneuvance, Enflonsia
Exact Sciences Corporation $129.43 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Welch Allyn $128.13 2020
Corium, LLC $120.26 2022-2025 Azstarys
Amgen INC. $116.95 2019-2025 Repatha, Otezla, Repatha
Ironshore Pharmaceuticals INC. $113.14 2019-2024 Jornay Pm
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $111.62 2024-2025 Caplyta
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $103.08 2023-2024 Xifaxan
E.R. Squibb & Sons, L.L.C. $92.77 2019
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $90.18 2019-2023 Jardiance
Sanofi-Aventis U.S. LLC $73.27 2022-2023
Takeda Pharmaceuticals U.S.A., INC. $71.03 2019-2022
Neurocrine Biosciences, INC. $55.97 2025
Heartflow, INC. $50.14 2024
Allergan, INC. $42.39 2019
Astellas Pharma US INC $38.73 2019
Supernus Pharmaceuticals, INC. $32.84 2023 Qelbree
Verona Pharma, INC. $27.42 2025 Ohtuvayre
Aimmune Therapeutics, INC. $22.49 2025 Zenpep
Gilead Sciences, INC. $22.48 2025
Collegium Pharmaceutical, INC. $22.17 2025 Jornay Pm
Ibsa Pharma INC. $20.59 2025 Licart, Flector, Tirosint
Ucb, INC. $17.53 2019
Otsuka America Pharmaceutical, INC. $16.82 2024 Rexulti
Xeris Pharmaceuticals, INC. $16.59 2024 Gvoke Hypopen
Alexion Pharmaceuticals, INC. $16.34 2019
Cranial Technologies, INC $15.97 2023 Doc Band
Celgene Corporation $14.25 2019
Abbott Laboratories $13.64 2025 Freestyle Libre 3
Teva Pharmaceuticals USA, INC. $13.44 2024 Austedo Xr
Janssen Pharmaceuticals, INC $13.41 2019
Sumitomo Pharma America, INC. $0.79 2023 Gemtesa

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David Knox Booth

$4,111.57

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk INC
Context
The $646 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/188352/david-knox-booth

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.